Osteoarthritis Therapeutics Market Analysis (2024-2030)

The Osteoarthritis Therapeutics Market is projected to expand from USD 7.29 million in 2023 to USD 10.75 million by 2030, demonstrating a robust Compound Annual Growth Rate (CAGR) of 5.7% during the forecast period from 2024 to 2030. This growth trajectory is primarily fueled by the increasing adoption of Visco supplementation and the rising population of elderly individuals.

Industry Insights:

Historically, chondroitin sulfate has demonstrated significant efficacy in alleviating discomfort and improving manual dexterity among osteoarthritis patients. Alleviating pain and restoring functional capacity constitute primary objectives in osteoarthritis management. Effective outcomes often necessitate a combination of non-pharmacological and pharmacological interventions. Commonly utilized supplements by Australian and American osteoarthritis patients include Omega-3 fatty acids, glucosamine, chondroitin, vitamins, methylsulfonylmethane (MSM), and herbal remedies. Osteoarthritis is recognized as a disability by the Social Security Administration (SSA), making individuals eligible for Social Security disability benefits upon meeting specific diagnostic criteria outlined in the SSA's Blue Book. Pain management for osteoarthritis typically involves opioids, oral analgesics, and parenteral pain relievers. While orthopedic braces are incorporated into noninvasive pain management approaches, pharmacological interventions remain widely prevalent due to their ease of administration and cost-effectiveness. Various medications, including oral analgesics, topical agents, intra-articular agents, and nutraceuticals, have demonstrated efficacy in reducing chronic pain by up to 30%. However, the substantial cost associated with treatment presents a significant impediment to market growth.

Impact of COVID-19 on the Osteoarthritis Therapeutics Market:

The COVID-19 pandemic, caused by the novel coronavirus, has exerted unprecedented strain on global healthcare systems since its emergence in Wuhan, China, in December 2019. Osteoarthritis patients have faced disruptions in accessing healthcare services, adverse lifestyle changes, and adverse effects on overall well-being and mental health during the pandemic. Particularly detrimental consequences include the postponement or cancellation of elective joint replacement surgeries. While temporary delays in surgical interventions may not directly exacerbate disease progression, prolonged immobility due to pain and stiffness can lead to muscle atrophy, weight gain, and diminished quality of life. Despite experiencing debilitating pain, patients with severe osteoarthritis should not endure untreated symptoms. Implementing a multimodal approach to osteoarthritis management during the pandemic can significantly ameliorate symptoms and promote a culture of collaborative primary care. Healthcare providers should prioritize scheduling regular follow-up appointments, leveraging telemedicine where feasible to address patient needs effectively. Moreover, despite challenges posed by reduced opportunities for aerobic exercise during the pandemic, adherence to a nutritious diet emphasizing adequate protein intake should be emphasized during follow-up visits. Such strategies have demonstrated efficacy in reducing pain, enhancing physical function and activity, decreasing reliance on analgesic medications, and minimizing the need for sick leave due to knee and hip osteoarthritis.

Market Drivers:

Growing Adoption of Visco Supplementation and Increasing Elderly Population:

Osteoarthritis prevalence correlates with aging and is more prevalent among individuals with comorbidities such as cardiovascular disease, obesity, and diabetes. The global increase in life expectancy has resulted in a burgeoning elderly population, consequently driving higher incidence rates of osteoarthritis and elevating per capita demand for therapeutic interventions. Visco supplementation represents a promising avenue for osteoarthritis management, offering relief from pain, stiffness, and inflammation in affected joints. The rising prevalence of osteoarthritis coupled with extensive utilization of these agents for pain management is poised to fuel market growth. Furthermore, visco supplementation confers substantial advantages over centrally acting opioid analgesics and central neuraxial blockade for surgical patients.

Market Restraints:

Shortage of Skilled Personnel and High Treatment Costs:

A scarcity of proficient personnel capable of administering appropriate interventions may impede the growth of the global osteoarthritis therapeutics market over the forecast period. Additionally, the substantial financial outlay required for treatment modalities, including specialized medications and surgical procedures, represents a significant barrier to market expansion.

Osteoarthritis Therapeutics Market - By Type:

• Ankle Osteoarthritis
• Hip Osteoarthritis
• Knee Osteoarthritis
• Shoulder Osteoarthritis
• Other Anatomies

In terms of type, Knee osteoarthritis stands out as a significant contributor to disability among the elderly population globally. An article published in December 2020 titled "Global, Regional Prevalence, Incidence and Risk Factors of Knee Osteoarthritis in Population-Based Studies" reported approximately 654.1 million individuals aged forty years and older living with osteoarthritis worldwide. The study further highlighted a 16% incidence of osteoarthritis among people aged 15 and above, escalating to a prevalence rate of 22.9% among those aged forty and older. For instance, as per data from the Eurostat Statistics report in June 2021, approximately 20.6% of Europe's population was aged sixty-five and above, with the proportion of individuals aged eighty and older expected to increase by two and a half times, from 5.9% in 2020 to 14.6% in 2022, thereby contributing to the expansion of the osteoarthritis therapeutics market.

Osteoarthritis Therapeutics Market - By Application:

• Hospitals
• Clinics
• Others

Regarding application, the hospital segment is projected to experience notable growth due to the rising prevalence of knee joint pain and other joint-related ailments, which are expected to propel market expansion during the forecast period. Hospitals held the largest market segment share in 2022 and are anticipated to maintain dominance.

Osteoarthritis Therapeutics Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East
• Africa

Geographically, the North American market is poised for growth owing to an increasing incidence of chronic diseases, a growing geriatric population, and lifestyle changes among individuals. Consequently, the adoption of various treatments and medications is on the rise in the region. Within North America, the United States is expected to retain a significant share in the osteoarthritis therapeutics market compared to Canada and Mexico. According to the National Public Health Agenda for Osteoarthritis 2020 Update by the Osteoarthritis Action Alliance, osteoarthritis is the most prevalent form of arthritis in the United States, affecting 1 in 7 adults, approximately 32.5 million people, with over 50% of affected adults in the working age group. Furthermore, factors such as the availability of advanced treatment options, government reimbursement policies, and increased research and development activities for novel therapeutics and treatment introductions in North America are expected to fuel market growth in the region. In Europe, Western Europe dominates the regional market, with significant contributions from Germany, the United Kingdom, and France. Conversely, Eastern Europe is witnessing rapid growth due to extensive untapped market opportunities. The Asia Pacific region is experiencing the fastest growth globally, attributed to a large patient population.

Osteoarthritis Therapeutics Market Share - By Company:

1. Pfizer, Inc.
2. Bayer AG
3. Horizon Therapeutics PLC
4. Glaxosmithkline PLC
5. Anika Therapeutics Inc.
6. Eli Lilly
7. Zimmer Biomet Holdings Inc.
8. Sanofi
9. Johnson & Johnson
10. Abbott
11. Novartis AG
12. Ferring Pharmaceuticals
13. Others

Key players such as Pfizer, Inc., Bayer AG, Horizon Therapeutics PLC, Glaxosmithkline PLC, Anika Therapeutics Inc., Eli Lilly, Zimmer Biomet Holdings Inc., Sanofi, Johnson & Johnson, Abbott, Novartis AG, Ferring Pharmaceuticals, among others, are pivotal in the market. Mergers and acquisitions within the industry have facilitated diversification and enhancement of service offerings. For instance, in 2022, Kitov Pharma Ltd. (Israel) entered into an agreement with Coeptis Pharmaceuticals, aiding in the efficient distribution and commercialization of Consensi. Additionally, ZILRETTA, developed by Flexion Therapeutics, Inc. (US), received FDA approval. These companies are experiencing substantial growth due to ongoing product innovation supported by rapid technology adoption. Emerging firms in the region are focusing on vertical integration of their operations to effectively position themselves in the market. Moreover, collaborations with established brands are being pursued to strengthen global brand presence. Large companies are investing in research and development activities to create innovative products and expand their application areas. Furthermore, companies have utilized various strategies such as mergers and acquisitions to foster growth.

Notable Happenings in the Osteoarthritis Therapeutics Market in the Recent Past:

• Product Launch: In November 2022, Alkem Laboratories introduced Ibuprofen and Famotidine tablets, designed to alleviate symptoms of rheumatoid arthritis and osteoarthritis in the United States market.